Related party transactions	6 Months Ended
Jun. 30, 2020
Related party transactions
Related party transactions	11. Related-party transactions Historically, the Company has received consulting and management services from one of its investors. During the three and six months ended June 30, 2020, there were no consulting and management services provided by this investor. During the three and six months ended June 30, 2019 the total amount of services provided by this investor was de minimis. As of June 30, 2020, there were no amounts payable related to consulting and management service fees provided by this investor. Additionally, during the three and six months ended June 30, 2020, the Company received board and scientific advisory services from two of its prior executives, Steven M. Paul, M.D., the Company’s former President and Chief Executive Officer, and Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Paul for services provided during each of the three and six months ended June 30, 2020 and 2019 was $50 thousand and $0.1 million, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and six months ended June 30, 2020 was $0.1 million and $0.2 million, respectively. Under the collaboration agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization of certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of June 30, 2020, the Company had approximately $12.7 million in related party collaboration receivable associated with Neurocrine.

Related party transactions

6 Months Ended

Jun. 30, 2020

11. Related-party transactions

Historically, the Company has received consulting and management services from one of its investors. During the three and six months ended June 30, 2020, there were no consulting and management services provided by this investor. During the three and six months ended June 30, 2019 the total amount of services provided by this investor was de minimis. As of June 30, 2020, there were no amounts payable related to consulting and management service fees provided by this investor.

Additionally, during the three and six months ended June 30, 2020, the Company received board and scientific advisory services from two of its prior executives, Steven M. Paul, M.D., the Company’s former President and Chief Executive Officer, and Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Paul for services provided during each of the three and six months ended June 30, 2020 and 2019 was $50 thousand and $0.1 million, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and six months ended June 30, 2020 was $0.1 million and $0.2 million, respectively.

Under the collaboration agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization of certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of June 30, 2020, the Company had approximately $12.7 million in related party collaboration receivable associated with Neurocrine.